Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …

Most patients with Alzheimer's disease present with amnestic problems; however, a
substantial proportion, over-represented in young-onset cases, have atypical phenotypes …

Background Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau
phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau …

Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset
dementia and presents with early social–emotional–behavioural and/or language changes …

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …

Objective To develop evidence-informed, expert consensus research diagnostic criteria for
traumatic encephalopathy syndrome (TES), the clinical disorder associated with …

Neurodegenerative diseases share the fact that they derive from altered proteins that
undergo an unfolding process followed by formation of β-structures and a pathological …

Background In March 2020, the World Health Organization declared a global pandemic due
to the novel coronavirus SARS-CoV-2 and several governments planned a national …

Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established
biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain …